Incyte Co. (NASDAQ:INCY) Shares Sold by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB reduced its holdings in Incyte Co. (NASDAQ:INCY) by 37.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,200 shares of the biopharmaceutical company’s stock after selling 1,300 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Incyte were worth $152,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in INCY. Point72 Asset Management L.P. acquired a new stake in shares of Incyte during the 3rd quarter worth $156,611,000. Mizuho Securities USA LLC boosted its holdings in Incyte by 13,814.7% in the third quarter. Mizuho Securities USA LLC now owns 2,000,100 shares of the biopharmaceutical company’s stock valued at $132,207,000 after acquiring an additional 1,985,726 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Incyte by 29.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,609,220 shares of the biopharmaceutical company’s stock valued at $106,369,000 after acquiring an additional 364,169 shares during the period. Robeco Institutional Asset Management B.V. increased its stake in Incyte by 5.9% during the third quarter. Robeco Institutional Asset Management B.V. now owns 1,265,966 shares of the biopharmaceutical company’s stock worth $83,680,000 after acquiring an additional 70,596 shares during the last quarter. Finally, Barclays PLC raised its holdings in shares of Incyte by 8.1% in the 3rd quarter. Barclays PLC now owns 1,031,932 shares of the biopharmaceutical company’s stock worth $68,208,000 after purchasing an additional 77,542 shares during the period. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

Incyte Stock Performance

Shares of INCY stock opened at $74.95 on Friday. The stock has a market capitalization of $14.44 billion, a price-to-earnings ratio of 535.40, a PEG ratio of 0.54 and a beta of 0.70. Incyte Co. has a one year low of $50.35 and a one year high of $83.95. The company’s 50-day simple moving average is $71.81 and its 200-day simple moving average is $69.04. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.82 and a current ratio of 1.87.

Insider Buying and Selling at Incyte

In other news, EVP Vijay K. Iyengar sold 6,043 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $75.38, for a total value of $455,521.34. Following the transaction, the executive vice president now directly owns 30,658 shares in the company, valued at approximately $2,311,000.04. This trade represents a 16.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Thomas Tray sold 650 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $70.64, for a total transaction of $45,916.00. Following the sale, the insider now directly owns 23,962 shares of the company’s stock, valued at approximately $1,692,675.68. This represents a 2.64 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 19,695 shares of company stock worth $1,444,356 over the last quarter. 17.60% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on INCY. Morgan Stanley boosted their target price on Incyte from $64.00 to $69.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 30th. Wells Fargo & Company increased their price objective on shares of Incyte from $68.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Thursday, December 19th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $70.00 price target on shares of Incyte in a research report on Thursday, January 23rd. JPMorgan Chase & Co. raised their price objective on Incyte from $65.00 to $71.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Finally, William Blair reaffirmed an “outperform” rating on shares of Incyte in a research report on Friday, December 13th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Incyte has an average rating of “Hold” and a consensus target price of $75.71.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.